Regeneron Pharmaceuticals, Inc. (LON:0R2M)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 45.47B |
| Revenue (ttm) | 11.34B |
| Net Income (ttm) | 3.52B |
| Shares Out | n/a |
| EPS (ttm) | 30.62 |
| PE Ratio | 12.90 |
| Forward PE | n/a |
| Dividend | 0.70 (0.12%) |
| Ex-Dividend Date | Feb 20, 2025 |
| Volume | 181 |
| Average Volume | 592 |
| Open | 550.30 |
| Previous Close | 549.54 |
| Day's Range | 545.42 - 560.00 |
| 52-Week Range | 545.42 - 998.57 |
| Beta | n/a |
| RSI | 32.18 |
| Earnings Date | Apr 29, 2025 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.
Financial numbers in USD Financial StatementsNews
Biocon Biologics' Yesafili to enter US market, after agreement with Regeneron
Biocon Biologics has reached a settlement with Regeneron, allowing the launch of Yesafili, its biosimilar eye drug, in the US by the second half of 2026. Approved by the USFDA as an interchangeable bi...
Biocon shares jump 3% as its subsidiary secures US market entry for Yesafili
Biocon Ltd. shares surged 3% after its subsidiary, Biocon Biologics Ltd., announced a major breakthrough in the U.S. market with the confirmed entry of Yesafili™ (aflibercept-jbvf)—an interchangeable ...
Biocon Biologics secures U.S. market entry for Yesafili™, an interchangeable biosimilar to Eylea®
Biocon Biologics Ltd., a subsidiary of Biocon Ltd., has announced a significant milestone in its U.S. expansion with the confirmation of a market entry date for Yesafili™ (aflibercept-jbvf), an interc...
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporter...
Trump says US pharma tariffs coming in not-too-distant future
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Even as President Donald Trump paused the reciprocal tariffs for 90 days on Wednesday, he later confirmed in a conversation with reporters at his Oval Office that pharmaceutical companies would face t...
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties...
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturin...
Explainer: Prescription drugs become a target in Trump's trade war
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t...
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squ...
Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Several exemptions exist among President Donald Trump ‘s broad tariffs , which were announced on Wednesday . The biopharma industry has historically been shielded from tariffs, including during Trump’...
RFK Jr. 'needs a lot of help and expertise' on science, says Regeneron CEO
Regeneron CEO Leonard Schleifer on Tuesday said that Health and Human Services Secretary Robert F. Kennedy Jr.
Regeneron CEO Leonard Schleifer on tariffs: Let's make sure the Europeans pay their fair share
Regeneron founder, chair and CEO Leonard Schleifer joins 'Squawk Box' to discuss the impact of President Trump's tariff policies on biotech and pharmaceuticals, his thoughts on HHS Secretary RFK Jr., ...
Regeneron CEO Leonard Schleifer on tariffs: Let's make sure the Europeans pay their fair share
Regeneron founder, chair and CEO Leonard Schleifer joins 'Squawk Box' to discuss the impact of President Trump's tariff policies on biotech and pharmaceuticals, his thoughts on HHS Secretary RFK Jr., ...
Watch CNBC's full interview with Regeneron CEO Leonard Schleifer
Regeneron founder, chair and CEO Leonard Schleifer joins 'Squawk Box' to discuss the impact of President Trump's tariff policies on biotech and pharmaceuticals, his thoughts on HHS Secretary RFK Jr., ...
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adu...
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils
Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025
TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2025 financial and operating results on Tuesday...
Lawsuit Notice: Investors who hold Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares should contact the Shareholders Foundation
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Inves...
Opthea Phase 3 Trial Fails To Meet Primary Endpoint, Faces Financial Uncertainty
On Monday, Opthea Limited (NASDAQ: OPT) released results from its global Phase 3 clinical trial COAST in patients with wet age-related macular degeneration (wet AMD) . The trial evaluated the efficac...